An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.

J Hematol Oncol · 2020 · PMC7160905 · PMID 32295630

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A reduction in bioluminescence in T22-GFP-H6-Auristatin-treated, as compared to the VEH-treated group was evident soon after treatment initiation, for full-body emission, bone marrow emission, and extramedullar site emission, all measured sites becoming highly significant at day 8 after treatment initiation, a significance that was maintained until the end of the experiment (day 13) (Table 1 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.